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Abstract
Background—Coronary computed tomography angiography (coronary CTA) can prognosticate 
outcomes in patients without modifiable risk factors over medium term follow-up. This ability was 
driven by major adverse cardiovascular events (MACE).
Objective—Determine if coronary CTA could discriminate risk of mortality with longer term 
follow-up. In addition we sought to determine the long-term relationship to MACE.
Methods—From 12 centers, 1884 patients undergoing coronary CTA without prior coronary 
artery disease (CAD) or any modifiable CAD risk factors were identified. The presence of CAD 
was classified as none (0% stenosis), mild (1% to 49% stenosis) and obstructive (≥50% stenosis 
severity). The primary endpoint was all-cause mortality and the secondary endpoint was MACE. 
MACE was defined as the combination of death, nonfatal myocardial infarction, unstable angina, 
and late target vessel revascularization (>90 days).
Results—Mean age was 55.6 ± 14.5 years. At mean 5.6 ± 1.3 years follow-up, 145(7.7%) deaths 
occurred. All-cause mortality demonstrated a dose-response relationship to the severity and 
number of coronary vessels exhibiting CAD. Increased mortality was observed for >1 segment 
non-obstructive CAD (hazard ratio [HR]:1.73; 95% confidence interval [CI]: 1.07–2.79; p = 
0.025), obstructive 1&2 vessel CAD (HR: 1.70; 95% CI: 1.08–2.71; p = 0.023) and 3-vessel or left 
main CAD (HR: 2.87; 95% CI: 1.57–5.23; p = 0.001). Both obstructive CAD (HR: 6.63; 95% CI: 
3.91–11.26; p < 0.001) and non-obstructive CAD (HR: 2.20; 95% CI: 1.31–3.67; p = 0.003) 
predicted MACE with increased hazard associated with increasing CAD severity; 5.60% in no 
CAD, 13.24% in non-obstructive and 36.28% in obstructive CAD, p < 0.001 for trend.
Conclusions—In individuals being assessed for CAD with no modifiable risk factors, all-cause 
mortality in the long term (>5 years) was predicted by the presence of more than 1 segment of 
non-obstructive plaque, obstructive 1- or 2-vessel CAD and 3 vessel/left main CAD. Any CAD, 
whether non-obstructive or obstructive, predicted MACE over the same time period.
Keywords
Coronary computed tomographic; angiography; Coronary artery disease; All-cause mortality; 
Major adverse cardiovascular events
1. Introduction
Clinicians are frequently confronted with patients requiring assessment for chest pain or 
equivalent symptoms.1 While cardiovascular risk factors provide some guidance,2,3 there is 
no close association between traditional risk factors and the presence of atherosclerosis 
identified by coronary computed tomography angiography (coronary CTA).4 The prognostic 
utility of coronary artery disease (CAD) detected by coronary CTA in those with no 
medically modifiable risk factors has been described for the medium term only. Over this 
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time period (2.3 ± 1.2 years) the ability of coronary CTA to discriminate risk was largely 
driven by the combined endpoint of major adverse cardiovascular events (MACE) defined as 
death, nonfatal myocardial infarction, unstable angina, and late target vessel 
revascularization (>90 days).4 However, CAD identified on coronary CTA did not confer an 
increased risk of mortality in the medium term. The primary purpose of this study was 
therefore to determine the long term (>5 year) prognostic utility of CAD detected in 
coronary CTA with regards to all-cause mortality in patients with no modifiable risk factors. 
To do so, we conducted a sub-analysis of the long-term Coronary CT Angiography 
Evaluation for Clinical Outcomes: An International Multi-center (CONFIRM) registry.
2. Method
2.1. Patient population
The rationale and methods of the CONFIRM registry have been described previously.5 In the 
long term cohort of the CONFIRM registry, in which patients have a mean follow-up of 5.6 
years, 12086 patients were prospectively enrolled between February 2003 and December 
2009 across 12 sites in 6 countries within North America, Europe, and Asia. Enrolled sites 
collected clinical information on risk factors, clinical presentation and follow-up for all-
cause mortality and MACE in addition to coronary CTA data(5). Institutional review board 
approval was obtained at each center.
2.2. Inclusion criteria
Inclusion criteria1 age ≥ 18 years2; CAD evaluation by coronary CTA using a CT system 
with ≥64 detector rows3; clinically indication for CAD evaluation4; interpretable coronary 
CTA; and5 prospective data collection for CAD risk factors. Clinical indications were 
defined as angina-equivalent symptoms including pain, tightness, and pressure, shortness of 
breath, pre-surgical evaluation, and structural indications (e.g., pulmonary vein mapping). In 
addition, individuals without chest pain syndrome could be assessed for CAD in the context 
of congenital heart disease, risk assessment of CAD in individuals who were considered to 
have severe vascular disease or had a concerning family history of vascular disease.
2.3. Chest pain categorization
Categorization of chest pain was based on the Diamond-Forrester criteria for angina 
pectoris.6 At each site, symptom category was prospectively determined through either 
written survey or interview by a doctor or allied health professional.
2.4. Exclusion criteria
Exclusion criteria for our analysis were all patients with modifiable risk factors for coronary 
artery disease (n = 8501) and patients with known CAD (n = 1593) and those with missing 
data relating to modifiable risk factors (n = 73), stenosis assessment (n = 33) and age (n = 2). 
Modifiable coronary risk factors included diabetes mellitus, hypertension, dyslipidemia, and 
smoking. Standardized definitions for modifiable risk factors were used. Diabetes mellitus 
was defined as a fasting glucose level of 126 mg/dL (6.99 mmol/L) or higher and/or use of 
diabetic mediations. Hypertension was defined by a systolic blood pressure of 140 mm Hg 
or higher or diastolic blood pressure of 90 mm Hg or higher and/or use of antihypertensive 
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therapy. Dyslipidemia was defined as a total cholesterol level of 200 mg/dL (5.18 mmol/L) 
or above or the use of lipid lowering therapy. Patients were considered smokers if they 
currently smoke or quit smoking within 3 months prior to coronary CTA. Patients with prior 
known CAD defined by previous myocardial infarction, percutaneous coronary intervention, 
or coronary artery bypass surgery were excluded from analysis. Importantly, family history 
of CAD was not an exclusion criteria, it is not modifiable and affected patients were 
therefore included in the analysis.
2.5. Outcomes
The primary endpoint was all cause mortality. The secondary endpoint was major adverse 
cardiovascular events (MACE), defined as the combination of death, nonfatal myocardial 
infarction, unstable angina, and late target vessel revascularization (>90 days). At each 
individual institution a physician and/or research nurse, who was blinded to coronary CTA 
results, conducted follow-up for mortality and MACE. At United States sites death was 
determined by query of the Social Security Death Index. At all other sites direct interview 
and/or telephone contact and/or review of medical records was used to determine mortality 
and MACE.
2.6. Scan protocol and image reconstruction, analysis and interpretation
Coronary CTA image acquisition at each site was performed according to Society of 
Cardiovascular Computed Tomography guidelines. CT system of various types and vendors, 
either single or dual source were included, the only restriction being that all scanners were 
required to be 64–detector rows or greater. Coronary segments were scored for stenosis 
severity using a 16-segment coronary artery model with the intention-to-diagnose. The 
definition of coronary atherosclerosis as visualised on CT was any lesion ≥1 mm2 that 
existed either within the lumen of the coronary vessel or adjacent to the lumen that could be 
differentiated from surrounding pericardial tissue, epicardial fat, or the vessel lumen itself.5 
Stenosis severity was graded on a per-patient, per-vessel, and per-segment basis. In 
epicardial coronary arteries of at least 2 mm in diameter, atherosclerotic lesions were graded 
as normal (no atherosclerosis), mild (1%–49% stenosis), or obstructive (≥50% stenosis). 
Each lesion was interrogated via numerous methods including maximum intensity projection 
and multiplanar reconstruction along the transverse plane and several longitudinal axes.
2.7. Statistical analysis
Statistical calculations were performed using STATA, version 13 (StataCorp LP, College 
Station, Texas). Absolute counts and percentages were used for categorical variables and 
means ± standard deviations were used to express continuous variables. Categorical 
variables were compared with the Χ2 test or Fisher Exact test for cell counts<6 and 
continuous variables were analyzed with the student t test or Mann–Whitney two-sample 
test, as appropriate. The Χ2 test for trend was used to compare categorical variables across 
ordered groups. Time to death or MACE were analyzed using Kaplan–Meier survival curves 
and compared using the log-rank test. Predictors of death and MACE were assessed using 
univariable and multivariable Cox proportional hazards models and the resulting hazard 
ratios (HR) and 95% confidence intervals were reported. Multivariate models were adjusted 
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for age, sex ± family history. Statistically significant difference was defined as thos with a 
two tailed p-value of <0.05.
3. Results
3.1. Study population
The CONFIRM long term cohort comprises 12086 patients of which 1593 individuals with a 
history of myocardial infarction, target vessel revascularization, cardiac transplant and loss 
to MACE follow-up were excluded. An additional 8574 individuals had medically 
modifiable CAD risk factors and were excluded from the analysis (hypertension, 1514; 
dyslipidemia, 3429; diabetes mellitus, 3333; smoking, 225). The final study cohort consisted 
of 1919 individuals. Complete follow-up was available in 1884 (98%), with 35 individuals 
lost to follow-up. A smaller cohort of 885 individuals had MACE follow–up data available 
for analysis.
The overall study cohort was middle-aged (mean age, 56 ± 15 years; 60% male patients), 
with a 24% prevalence of obstructive CAD. The mean follow-up period was 5.6 ± 1.3 years. 
The majority of study individuals presented with low (33.8%) or intermediate (58.5%) 
pretest likelihood of obstructive CAD. Only a minority (7.7%) had a high pretest likelihood 
of CAD (Table 1).
3.2. Clinical characteristics associated with CAD and all-cause mortality
There were 145 deaths in the entire cohort. Chest pain typicality information was available 
in 1518 patients. All-cause mortality was associated with higher age (HR 1.07, p < 0.001) 
but not male sex (HR 0.91, p = 0.58). There was a paradoxical relationship between chest 
pain typicality and mortality with atypical chest pain patients having a reduced mortality 
(HR 0.58, p = 0.04), while non-anginal chest pain (HR 1.28, p = 0.36) and typical angina 
(HR 0.96, p = 0.88) had no relationship to mortality when compared to asymptomatic 
patients (Table 2).
3.3. Effect of per-patient and per-vessel CAD in coronary CTA on mortality
A dose-response relationship was observed for increased hazards of death for non-
obstructive, 1- or 2-vessel obstructive CAD and 3 vessel/left main obstructive CAD (Fig. 1). 
Importantly, the absence of CAD in coronary CTA was associated with a low rate of incident 
death (annualized mortality: 0.69%; 95% CI: 0.5–0.95%). Using multivariable Cox 
regression analysis considering age and sex, time to all-cause mortality was predicted by 
per-vessel obstructive 1- or 2-vessel CAD as well as 3 vessel/left main CAD (Table 3). 
Further analysis of the burden of non-obstructive disease, as determined by number of 
segments involved, showed that >1 segment of non-obstructive CAD predicted mortality 
(Table 3). Mortality rate after a mean of 5.6 years follow-up in those with no CAD was 
3.95%. Mortality increased to 9.48% in patients with non-obstructive CAD and i to 13.5% in 
patients with obstructive CAD (p for trend < 0.001).
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3.4. Effect of per-patient and per-vessel CAD in coronary CTA on MACE
In the MACE cohort, the presence of any form of CAD, obstructive (HR: 6.63; 95% CI: 
3.91–11.26; p < 0.001) or non-obstructive (HR: 2.20; 95% CI: 1.31–3.67; p = 0.003) 
predicted MACE (Fig. 2). There was an increased hazard for MACE with increasing CAD 
severity (Table 4). The incidence of MACE increased from 5.6% in those without CAD to 
13.24% in those with non-obstructive disease and to 36.28% in those with obstructive CAD 
(p < 0.001) for trend (Table 5).
4. Discussion
This sub-study of the CONFIRM long term registry signifies the first prospective 
international multicenter dataset to correlate CAD diagnosed on coronary CTA in 
individuals with no modifiable risk factors to long-term (>5 year) all-cause mortality. This 
analysis builds on prior work which noted a relationship between CCTA diagnosed disease 
and MACE in the medium-term, but did not show this relationship with all-cause mortality.4 
Importantly, there was a relationship between the severity of obstructive CAD and long term 
all-cause mortality. Also, we observed a relationship between the presence of nonobstructive 
atherosclerosis in >1 coronary segment and mortality. However, while the presence of any 
obstructive disease conferred an incremental risk of MACE, there was no significant 
difference in MACE rates when stratified by the extent of obstructive disease. This may 
reflect the fact that the majority of our MACE events were late revascularizations.
Our study is in keeping with prior published data from phase 1 of the CONFIRM registry 
which analyzed all patients suspected of having CAD, regardless of risk factors, for a 
median of 2.3 years. In that larger cohort (n = 24 775) individuals had increased mortality 
associated with both obstructive and non-obstructive disease.7 Other investigators have 
shown that after more than 6 years of follow-up, 3-vessel non-obstructive and any 
obstructive CAD, diagnosed by coronary CTA, were independent predictors of mortality in a 
multivariable model with an influence of the burden of CAD on mortality.8
Accurately estimating the pre-test likelihood of significant CAD is fundamental to determine 
subsequent decisions for diagnostic testing and resultant management.8 In our cohort, the 
vast majority of individuals (92%) were classed as either low or intermediate pre-test 
likelihood of obstructive CAD. This is at odds to the observed rates of obstructive CAD 
(24%) and non-obstructive CAD (26.3%). This highlights a discrepancy between the clinical 
assessment of CAD and the presence and extent of CAD demonstrated by coronary CTA, 
which is potentially particularly pronounced in individuals without traditional modifiable 
risk factors. These findings are not dissimilar to the vast amount of data emphasizing that 
coronary calcium is a better predictor of cardiac events than traditional risk factors. Hou et 
al. demonstrated an incremental value of coronary calcium and coronary CTA for predicting 
MACE, with areas under the receiver-operating characteristic curves improving to from 0.71 
for clinical risk factors alone to 0.82 and 0.93, respectively (both p < 0.001).9
In our cohort, those deemed as low pretest likelihood of CAD had lower all-cause mortality, 
while patients with a high pre-test likelihood of CAD showed a signal towards increased 
mortality. It is however important to acknowledge that the Diamond Forrester pre-test model 
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was designed to assess probability of having significant CAD in symptomatic patients and 
not to predict downstream events.6 In addition, the Diamond Forrester risk score was 
developed for use in higher risk individuals planned for invasive coronary angiography and 
not low-risk cohorts such as ours or other groups typically scheduled for coronary CTA. 
Recently, risk tools using clinical risk factors and coronary CTA findings in combination 
have been developed. For example, an optimized prognostic score, the “CONFIRM 
Score”,10 integrates the distribution and severity of disease as identified on coronary CTA 
and clinical risk factors to determine risk. It resulted in an impressive net reclassification 
improvement of 49% compared to a clinical risk score, the NCEP ATP III score,11 in 
predicting all-cause mortality.10 These findings, similar to our analysis, emphasize the 
clinical importance of CAD identified by coronary CTA.
This study is not without limitations. Firstly, the details of downstream management 
decisions are not known and therefore the potential impact such decisions may have on 
downstream events is unclear. Importantly however, although information regarding 
downstream management was lacking, treatment bias would result in a reduction of events in 
those with atherosclerosis. Secondly, although all-cause mortality was the primary outcome, 
the precise cause of death for each patient was not available. This is particularly important 
considering that almost 4% of patients without any atherosclerosis died after 5.6 years of 
follow-up. This, however, must be interpreted in the context of the baseline population 
annualised death rate in this age group, which is approximately 1%.12 Thirdly, our study 
focused entirely on stenosis assessment without taking into consideration other information 
available from coronary CTA such as plaque characteristics which may also influence the 
likelihood of ischemia and outcomes.13,14
5. Conclusion
In individuals without modifiable cardiovascular risk factors undergoing coronary CTA, 
long-term mortality was predicted by the presence of more than 1 segment of non-
obstructive plaque, obstructive 1- or 2-vessel CAD as well as 3 vessel/left main CAD. In 
addition, any degree of CAD, whether non-obstructive or obstructive, predicted MACE over 
the same time period.
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Figure 1. 
Unadjusted Kaplan–Meier curve for mortality-free survival on the basis of the presence of 
no CAD, non-obstructive CAD, 1&2 vessel obstructive CAD and 3 vessel obstructive & left 
main CAD for individuals without modifiable CAD risk factors (p values based on log-rank 
tests).
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Figure 2. 
Unadjusted Kaplan–Meier curve for MACE-free survival on the basis of the presence of no 
CAD, non-obstructive CAD, 1&2 vessel obstructive CAD and 3 vessel obstructive & left 
main CAD for individuals without modifiable CAD risk factors (p values based on log-rank 
tests).
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Table 1
Baseline clinical and CAD characteristics study population N = 1884.
Characteristic Datum n (%)
Age (years) 55.6 ± 14.5
Male patients 1122 (59.6)
Chest pain typicality:
Typical 241 (15.9)
Atypical 492 (32.4)
Non-anginal 218 (14.4)
Asymptomatic 567 (37.4)
Family history status
Family history of CAD 589 (31.3)
No family history of CAD 1295 (68.7)
Pretest likelihood of CAD
Low ≤0.10 513 (33.8)
Intermediate 0.11–0.89 887 (58.5)
High ≥0.90 116 (7.7)
CCTA identified CAD
Normal 936 (49.7)
Non-obstructive 496 (26.3)
Obstructive (≥50%) 452 (24.0)
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Table 2
Chest Pain Typicality and All Cause Death (n = 1518).
Chest pain typicality n = 1518 No death (n = 1418) n (%) Death (n = 100) n (%) Hazard ratio P-value
Typical 224 (15.8) 17 (17.0) 0.96 0.88
Atypical 471 (33.2) 21 (21.0) 0.58 0.04
Non-anginal 197 (13.9) 21 (21.0) 1.28 0.36
Asymptomatic 526 (37.1) 41 (41.0) 1 0.44
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Table 3
Hazard Ratio Of All Cause Mortality Stratified By Presence And Extent Of CAD On A Per-Patient And Per-
Vessel Basis.
CCTA result Risk-adjusteda hazard ratio HR (95% CI) P-value
Per-patient CAD
Non obstructive 1.49 (0.96–2.32) 0.078
Obstructive 1 & 2 Vx Dx 1.7 (1.08–2.71) 0.023
Obstructive 3 Vx Dx & LM 2.86(1.57–5.23) 0.001
Non obstructive 1 segment 1.04 (0.53–2.05) 0.90
Non obstructive > 1 segment 1.73 (1.07–2.79) 0.025
Obstructive CAD 1.94 (1.25–3.00) 0.003
aAdjusted for age & sex.
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Table 4
Hazard Ratio Of MACE Stratified By Presence And Extent Of CAD On A Per-Patient And Per-Vessel Basis.
CCTA result Univariable hazard ratio HR (95% CI) P-value Risk-adjusteda hazard ratio HR (95% CI) P-value
Per-patient CAD
Non Obstructive CAD 2.42 (1.48–3.97) <0.001 2.20 (1.31–3.67) 0.003
Obstructive CAD 7.71 (4.77–12.48) <0.001 6.63 (3.91–11.26) <0.001
Per-vessel CAD
Non Obstructive CAD 2.42 (1.48–3.97) <0.001 2.20 (1.31–3.68) 0.003
Obstructive 1VD 7.75 (4.63–12.98) <0.001 6.65 (3.79–11.65) <0.001
Obstructive 2VD 7.71 (3.64–16.35) <0.001 6.62 (3.00–14.61) <0.001
Obstructive 3VD/LM 7.23 (1.72–30.36) 0.007 6.48 (1.53–27.51) 0.011
aAdjusted for age, sex and family history.
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Table 5
All Cause Mortality And MACE Rates Stratified By The Presence And Severity Of CAD.
Event Normal n (%) Non-obstructive CAD n (%) Obstructive CAD n (%) P-value (trend)
Overall cohort n = 1884 936 496 452
Death 37 (4.0) 47 (9.5) 61 (13.5) <0.001 (<0.001)
MACE cohort n = 885 500 272 113
MACE 28 (5.6) 36 (13.2) 41 (36.3) <0.001 (<0.001)
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